Global Gynecology Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

·9 min read

DUBLIN, Sept. 16, 2021 /PRNewswire/ -- Gain comprehensive access to over 400 gynecology deal records from this report "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" that has been added to's offering.

Research and Markets Logo
Research and Markets Logo

This report provides a full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Gynecology partnering deals

  • Financial deal terms for headline, upfront and royalty by stage of development

  • Gynecology partnering agreement structure

  • Gynecology partnering contract documents

  • Top Gynecology deals by value

  • Most active Gynecology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gynecology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gynecology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gynecology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gynecology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gynecology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gynecology partnering deals by specific Gynecology target announced since 2010. The chapter is organized by specific Gynecology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Report Scope

Global Gynecology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.

Global Gynecology Partnering 2010 to 2021 includes:

  • Trends in Gynecology dealmaking in the biopharma industry since 2010

  • Analysis of Gynecology deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to hundreds of Gynecology deal contract documents

  • Comprehensive access to over 400 Gynecology deal records

  • The leading Gynecology deals by value since 2010

  • Most active Gynecology dealmakers since 2010

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In Global Gynecology Partnering 2010 to 2021, available deals and contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gynecology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 400 gynecology deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are the sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates

Chapter 4 - Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value

Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available

Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target


Companies Mentioned

  • 23andMe

  • Abbvie

  • Accord Healthcare

  • Acerus

  • Advaxis

  • Adynxx

  • AEterna Zentaris

  • Agency for Healthcare Research and Quality

  • Agile Therapeutics

  • AirStrip Technologies

  • Albion

  • Allakos

  • Alvogen

  • American Dental Association

  • Amgen

  • Amos Gazit

  • ANI Pharmaceuticals

  • ApolloBio

  • Arbor Pharmaceuticals

  • Arc Medical Design

  • Ascend Therapeutics

  • ASKA Pharmaceuticals

  • Aspen Dental

  • ASPiRA Labs

  • AstraZeneca

  • Austrian Research Promotion Agency

  • Avion Pharmaceuticals

  • Aytu BioScience

  • Back Bay Scientific

  • Bavarian Nordic

  • Bayer

  • Bayer Healthcare

  • Baylor College of Medicine

  • Beckman Coulter

  • Beijing Genomics Institute (BGI)

  • Besins Healthcare

  • Bill and Melinda Gates Foundation

  • Biocon

  • Biomnis

  • Biotech Inc

  • BL&H

  • Bluebird Bio

  • BMV Medica

  • Boston Scientific

  • Bristol-Myers Squibb

  • California Institute for Biomedical Research

  • Celmatix

  • Center for Human Genetics and Laboratory Medicine

  • Chinese Academy of Sciences

  • Chun Fo Pharmaceutical

  • Cipla Medpro

  • ClearSpec

  • Clinigen

  • CNC Biotech

  • Co-Diagnostics

  • Cocrystal Pharma

  • CommonSense

  • Common Sense

  • Consortia Health

  • Control Flo Medical

  • Cooper Companies

  • Coriell Life Sciences

  • CR Pharma

  • CVC Capital Partners

  • Cynosure

  • Debiopharm

  • DIAsource ImmunoAssays

  • Dilafor

  • Distal Access

  • Duchesnay

  • Duke University

  • DySIS Medical

  • Easton Pharmaceuticals

  • Egalet

  • El.En

  • Elanix Biotechnologies

  • EMD Serono

  • Emory University

  • EndoCeutics

  • European Board and College of Obstetrics and Gynaecology

  • European Organization for Research and Treatment of Cancer

  • European Union Regional Development Fund

  • Evestra

  • Evotec

  • Expedeon

  • Famy Care

  • Ferring Pharmaceuticals

  • Flo Health

  • Fogarty Institute for Innovation

  • Foresee Pharmaceuticals

  • Fougera Pharmaceuticals

  • Fuji Pharma

  • Genea Biomedx

  • Genoma

  • Genome Medical

  • German Cancer Research Center

  • Gilead Sciences

  • GlaxoSmithKline

  • GOG Foundation

  • Golden Valley Development

  • Good Start Genetics

  • Grunenthal

  • Guided Therapeutics

  • Gynica

  • Halt Medical

  • Hammock Pharmaceuticals

  • HealthNet

  • Helix

  • Helix BioPharma

  • Hologic

  • Hookipa Biotech

  • Hope Medicine

  • HTG Molecular Diagnostics

  • Igantia Therapeutics

  • iGenomix

  • Illumina

  • Imaxio

  • IncellDx

  • InnerOptic Technology

  • Innovus Pharmaceuticals

  • Inovio Pharmaceuticals

  • Intuitive Surgical

  • INVO Bioscience

  • Irvine Scientific

  • IsoRay

  • ITEM Medical Technologies

  • IviGen

  • Janssen Pharmaceuticals

  • Johns Hopkins University

  • Joylux

  • Karolinska Institute

  • Kissei Pharmaceutical

  • Kite Pharma

  • Knight Therapeutics

  • Kyoto University

  • Laboratory Corporation of America

  • Laccure

  • Lake Consumer Products

  • Lee's Pharmaceutical

  • LFB Biotechnologies

  • LifeCodexx

  • Lumara Health

  • Lumir Lab

  • Massachusetts General Hospital

  • McKesson

  • MD Anderson Cancer Center

  • MDNA Life Sciences

  • Meda

  • MEDCIS Pathlabs

  • Medical University of South Carolina

  • Medical University South Carolina

  • MediCare International

  • MediGene

  • MedikorPharma

  • MedImmune

  • Medinova

  • MedTech For Solutions

  • Medtronic

  • Mel-Mont Medical

  • MenoGeniX

  • Merck and Co

  • Merck KGaA

  • Merck Serono

  • Merus Labs International

  • MilanaPharm

  • Millendo Therapeutics

  • Ministry of Health (Turkey)

  • Mission Pharmacal

  • Mithra Pharmaceuticals

  • Mitsubishi Tanabe Pharma

  • Morphic Therapeutic

  • MSD

  • Mundipharma

  • MyBiotics Pharma

  • Mylan Laboratories

  • Myovant Sciences

  • Myrtle Potter & Company

  • Naka International

  • Natera

  • National Institute for Public Health and the Environment

  • National Institute on Aging

  • National Institutes of Health

  • Neoteric Technology

  • NextGen LifeLabs

  • Nobelpharma

  • Norgine

  • Northwestern University

  • Novation

  • Noven Pharmaceuticals

  • Novogene

  • NX Prenatal

  • OBP Medical

  • ObsEva

  • Olympus

  • OncoSec Medical

  • Oncotest

  • Oral Cancer Foundation

  • OvaGene Oncology

  • Oxford MEstar

  • Patient-Centered Primary Care Collaborative (PCPCC)

  • PaxGenBio

  • PCOS Challenge

  • PCOS Diva

  • PDS Biotechnology

  • Peking University

  • Perinatal Quality Foundation

  • PerkinElmer

  • Perrigo

  • Pfizer

  • PharmaJet

  • Pharmanest

  • Pharma Solutions Peru

  • Psyche Systems

  • Radius Health

  • Rebiotix

  • Recipharm

  • Reproductive Health Science

  • Reprogenetics

  • rEVO Biologics

  • Roche

  • Romark Laboratories

  • Royal Philips Electronics

  • Sanofi

  • Sanofi-Pasteur

  • Scholar Rock

  • Selecta Biosciences

  • Shandong Yaohua Medical Instrument

  • Shenghuo Medical

  • Shionogi

  • Shire Pharmaceuticals

  • Sims IVF

  • Sincopharm

  • Sirio Pharma

  • Skolkovo Foundation

  • Smith & Nephew

  • Smiths Medical

  • Society For Reproductive Investigation

  • Society of Gynecologic Oncology

  • SRI International

  • Starpharma

  • Strainprint Technologies

  • Sun Pharmaceutical

  • Surgicorp

  • Syn-The-All Pharmaceutical

  • SynteractHCR

  • Takeda Pharmaceutical

  • Tec-Pharma

  • Telenatal

  • Tesaro

  • Tessa Therapeutics

  • Teva Pharmaceutical Industries

  • Teva Pharmaceuticals USA

  • Theramex

  • TherapeuticsMD

  • Thermo Fisher Scientific

  • Transgene

  • Trimel Pharmaceuticals

  • Trivector Biomed

  • Trophogen

  • twoXAR

  • Unified Women's Clinical Research

  • University College Dublin Conway Institute

  • University Magna Graecia

  • University of Hong Kong

  • University of Michigan

  • University of Oxford

  • University of Siena

  • Upsher-Smith

  • Vaccibody

  • Valeo Pharma

  • Vertical Pharmaceuticals

  • Viramal

  • Virtus Health

  • VolitionRX

  • Wayne State University

  • Wellmed

  • Windsor Pharmaceuticals

  • Womens Choice Pharmaceuticals

  • Wuxi Apptec Laboratory Services

  • Xbrane Bioscience

  • Xisle Pharma Ventures Trust

  • ZenTech

  • Zhengzhou University

  • Zoetis

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716


View original content:

SOURCE Research and Markets

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting